Investigation of the current status and related factors of vancomycin-associated acute kidney injury in critically ill patients
- VernacularTitle:重症患者万古霉素相关急性肾损伤发生现状及相关因素分析
- Author:
Jie LI
1
;
Ying ZHANG
2
;
Danfei SONG
1
;
Kunming PAN
2
;
Xiaoyu LI
2
;
Qianzhou LYU
2
Author Information
1. Dept. of Pharmacy，Tongji Hospital of Tongji University，Shanghai 200065，China
2. Dept. of Pharmacy，Zhongshan Hospital，Fudan University，Shanghai 200032，China
- Publication Type:Journal Article
- Keywords:
Vancomycin;
Acute kidney injury;
critically ill patients;
Risk factors;
prognosis
- From:
China Pharmacy
2026;37(16):2144-2149
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the incidence and outcomes of vancomycin-associated acute kidney injury （VA-AKI） in critically ill patients， to analyze the independent risk factors for the development of VA-AKI and renal function outcomes in VA-AKI patients， and to evaluate the predictive performance of vancomycin treatment duration for VA-AKI occurrence， so as to provide reference for the rational and safe use of this drug.METHODS Clinical data of critically ill patients who received vancomycin during hospitalization in the intensive care unit of Zhongshan Hospital， Fudan University，from January 2022 to December 2024 were retrospectively collected. Patients were divided into the VA‑AKI group and the non‑AKI group according to the occurrence of VA‑AKI. Multivariate Logistic regression analysis was performed to screen for independent risk factors for VA‑AKI development and renal function outcomes in patients with VA‑AKI. The receiver operating characteristic （ROC） curve was used to analyze the predictive performance of vancomycin treatment duration for VA‑AKI.RESULTS A total of 1 484 patients were enrolled， among whom 287 developed VA‑AKI， with an incidence of 19.3%. The overall median time to onset was 2.5 days after vancomycin administration. Complicated hypertension， cardiac or renal insufficiency， hospital‑acquired sepsis/bacteremia， multiple organ failure， invasive mechanical ventilation during hospitalization， vancomycin treatment duration ≥10 days， and concomitant use of carbapenems or tacrolimus were independent risk factors for VA‑AKI （ P ＜0.05）. Concomitant use of vasopressors was an independent risk factor for renal function outcomes in patients with VA‑AKI （ P ＜0.05）. The area under the ROC curve （AUC） of the model using vancomycin treatment duration of predict the occurrence of VA-AKI was 0.624. At the optimal cut‑off value of 9.7 days， the sensitivity and specificity were 47.4% and 74.9%， respectively.CONCLUSIONS Critically ill patients have a relatively high incidence of VA-AKI， which mostly occurs in the early stage of vancomycin therapy. Patients with underlying cardiac-renal diseases， severe infection， requirement for mechanical ventilation， prolonged vancomycin therapy， and concomitant administration of carbapenems or tacrolimus are at high risk for VA-AKI. Concomitant vasopressor use affects renal function recovery in patients with VA-AKI. The predicted risk of acute kidney injury is higher when vancomycin treatment duration is ≥10 days.
